Novacyt PLC (LON:NCYT) said there had been “unprecedented interest” in its coronavirus diagnostic launched a week ago.
Its unit Primedesign has already received orders for 33,000 tests and requests for quotations for another 32,000 from over 30 countries. It has a high conversion rate from such interest.
In the same update, Novacyt said it had applied to the US Food & Drug Administration for emergency use approval. Here in Europe, it is planning to launch a CE-Mark approved version of the kit later this month that can be used for clinical diagnostic testing rather than just screening.
“We continue to support our new and existing customers and are working with the various regulatory authorities to try to make our nCoV test available to as many countries and laboratories as possible to support clinicians in reducing the spread of the disease," said chief executive Graham Mullis.